DOI: 10.36347/sjams.2018.v06i02.064

Pages: 797-801

Psoriasis is a complex, chronic, multifactorial, inflammatory disease. Objectives of this study were to determine the occurrence of metabolic co-morbidities such as cardiovascular disease, diabetes mellitus, hypertension, dyslipidemia, obesity, MetS and NAFLD in psoriatic patients and to compare their occurrence with controls and to determine if the presence of these metabolic co-morbidities is related to the severity of the psoriasis. This is a single centre case control study done at department of Dermatology, Venerology & Leprosy of a tertiary care centre of Indore. Three hundred patients with Psoriasis Vulgaris were consecutively enrolled over a period of one year from January 2017 to December 2017. Our cases included 300 patients with psoriasis above the age of 18 years and 300 controls. Patients with psoriasis had a higher BMI. 34.1% and 22.5% of patients with psoriasis had grade I and grade II obesity respectively Vs 52.4% and 14.4% among controls. Low HDL levels was the most common feature of metabolic syndrome (64%), followed by abdominal obesity (63%), raised fasting blood sugars (55%), triglyceridemia (34%) and hypertension (27%) in the psoriasis group. Metabolic syndrome and its individual components such as abdominal obesity, triglyceridemia, increased fasting blood sugars and hypertension were significantly more in patients with psoriasis than in controls. In our study there was a significant association between psoriasis and occurrence of MetS and its components like insulin resistance, hypertriglyceridemia, abdominal obesity, hypertension and raised fasting blood glucose. Therefore we propose that all psoriatic patients must be screened for cardiovascular risk factors and their predecessors i.e the metabolic disturbances, at the disease onset itself irrespective of severity and duration, especially those where systemic therapy is being considered or where there is a strong family history of vascular accidents.